NetworkNewsBreaks – BioLineRx (NASDAQ: BLRX) Reports Interim Results on Phase 2 Study of BL-8040 in Stem Cell Mobilization
BioLineRx (NASDAQ: BLRX) this morning reported partial results data from its open-label phase 2 trial for BL-8040 as a novel monotherapy approach for the mobilization and collection of blood forming stem and progenitor cells from the peripheral blood. Interim results from the initial cohort of donor and recipient pairs show that a single injection of BL-8040 mobilized sufficient amounts of cells required for transplantation at a level of efficacy similar to that achieved by using 4-6 injections of G-CSF, the current standard of care. So far, all transplant recipients have experienced a successful neutrophil engraftment. Recipients will continue to be…
